Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
Progress and challenges in targeting the SARS-CoV-2 papain-like protease
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …
Small molecules in the treatment of COVID-19
S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
Antiviral drug discovery for the treatment of COVID-19 infections
TI Ng, I Correia, J Seagal, DA DeGoey, MR Schrimpf… - Viruses, 2022 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …
Targeting SARS-CoV-2 proteases for COVID-19 antiviral development
The emergence of severe acute respiratory syndrome (SARS-CoV-2) in 2019 marked the
third occurrence of a highly pathogenic coronavirus in the human population since 2003. As …
third occurrence of a highly pathogenic coronavirus in the human population since 2003. As …
Inhibitors of sars-cov-2 plpro
The emergence of SARS-CoV-2 causing the COVID-19 pandemic, has highlighted how a
combination of urgency, collaboration and building on existing research can enable rapid …
combination of urgency, collaboration and building on existing research can enable rapid …
Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape
X Wu, M Go, JV Nguyen, NW Kuchel, BGC Lu… - Nature …, 2024 - nature.com
Papain-like protease (PLpro) is an attractive drug target for SARS-CoV-2 because it is
essential for viral replication, cleaving viral poly-proteins pp1a and pp1ab, and has de …
essential for viral replication, cleaving viral poly-proteins pp1a and pp1ab, and has de …
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …
SARS‐CoV‐2 papain‐like protease: structure, function and inhibition
Emerging variants of SARS‐CoV‐2 and potential novel epidemic coronaviruses underline
the importance of investigating various viral proteins as potential drug targets. The papain …
the importance of investigating various viral proteins as potential drug targets. The papain …